HighTide Therapeutics (HKSE:02511) Other Long-Term Liabilities : HK$2.17 Mil (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is HighTide Therapeutics Other Long-Term Liabilities?

HighTide Therapeutics's other long-term liabilities for the quarter that ended in Dec. 2023 was HK$2.17 Mil.

HighTide Therapeutics's quarterly other long-term liabilities increased from Dec. 2022 (HK$5.72 Mil) to Jun. 2023 (HK$1,612.86 Mil) but then declined from Jun. 2023 (HK$1,612.86 Mil) to Dec. 2023 (HK$2.17 Mil).

HighTide Therapeutics's annual other long-term liabilities declined from Dec. 2021 (HK$1,250.74 Mil) to Dec. 2022 (HK$5.72 Mil) and declined from Dec. 2022 (HK$5.72 Mil) to Dec. 2023 (HK$2.17 Mil).

HighTide Therapeutics Other Long-Term Liabilities Historical Data

The historical data trend for HighTide Therapeutics's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HighTide Therapeutics Other Long-Term Liabilities Chart

HighTide Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Other Long-Term Liabilities

HighTide Therapeutics Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23
Other Long-Term Liabilities	-	-	-	-	-

HighTide Therapeutics Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

HighTide Therapeutics Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of HighTide Therapeutics's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

HighTide Therapeutics (HKSE:02511) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HighTide Therapeutics Inc (HKSE:02511) » Definitions » Other Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

Ganli Second Road, 18B-102, Zhonghaixin Innovation Industry City, Jihua Neighborhood, Longgang District, Guangdong, Shenzhen, CHN, 518112

Website

https://www.hightidetx.com

HighTide Therapeutics Inc is a biopharmaceutical company specializing in the discovery, development and commercialization of multifunctional, multi-targeted therapies for the treatment of metabolic and digestive diseases. The company has developed a product pipeline of five product candidates in-house, covering nine indications in metabolic and digestive diseases among which, five are at clinical-stage. The Core Product, HTD1801 (berberine ursodeoxycholate), a new molecular entity, is a gut-liver anti-inflammatory metabolic modulator which targets multiple pathways pivotal to metabolic regulation, including those associated with metabolic and digestive diseases.

Executives

Ma Lixiong	2101 Beneficial owner
Liu Liping	2101 Beneficial owner
Li Li	2201 Interest of corporation controlled by you
The Core Trust Company Limited
Shan Miao	2201 Interest of corporation controlled by you
Medi Prosperity Capital Inc.	2201 Interest of corporation controlled by you
Hepalink Healthcare Partners I L.p	2201 Interest of corporation controlled by you
Hepalink Biotechnology Ii Limited	2101 Beneficial owner
Hepalink (hong Kong) Limited	2201 Interest of corporation controlled by you
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.	2501 Other
Wisdom Spring Group Limited
Tct (bvi) Limited
Baiyi Capital Limited	2101 Beneficial owner
Lai Hoi Man	2201 Interest of corporation controlled by you
Hongtu Capital Limited	2101 Beneficial owner

HighTide Therapeutics (HKSE:02511) Headlines

No Headlines